Author + information
- Eser Durmaz1,
- Hasan Ali Barman1,
- Burçak Kılıçkıran Avcı1,
- Hafize Uzun2,
- Remisa Girişken2,
- Bilgehan Karadağ1 and
- Zeki Öngen1
In-stent restenosis (ISR) occurs in 16% to 44% of patients with coronary artery disease treated with stenting. Clinical studies have suggested that the plasma renin activity (PRA) may play a role in ISR. Angiotensin-convertig enzyme inhibitors (ACE-I) have been reported to reduced the rate of ISR. This study aimed to clarify the role of PRA in the development of ISR in patients treated with stenting and already receiving ACE-I therapy.
The study popullation comprised 52 patients with ISR (group A) and 39 patients without ISR (group B). All patients were treated with ACE-I. In-stent restenosis, was defined as angiographic restenosis (> or = 50% diameter stenosis over one year after the intervention). Patients were excluded if they had heart failure of if they were known to have a low ejection fraction (<40%), uncontrolled hypertension, or overt nephropathy. PRA levels were measured at the time of coronary angiography.
The mean patient age was 59 years. Most patients were men (68.1%). Baseline characteristics including drug use were similar between groups (Table 1). No significant differences was found among patients with and without in-stent restenosis groups with respect to PRA (0.67±1.6 vs 0.57±0.9 ng/ml.h, P=0.74).
We did not find any relationship between the PRA and angiographic restenosis after coronary stenting.
|Group A (n= 52)||Group B (n = 39)|
|Age||60 ± 8||57 ± 12|
|Men (%)||35 (67.7)||27 (69.2)|
|Hypertension (%)||29 (54.7)||24 (45.3)|
|Diabetes (%)||16 (30.8)||12 (30.8)|
|LDL-cholesterol (mg/dL)||130 ± 42||128 ± 37|
|Creatinine (mg/dL)||0.99 ± 0.3||0.92 ± 0.3|